The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Xilio Therapeutics Inc shares valued at $30,870 were purchased by Shannon James Samuel on Jun 16 ’25. At $0.69 per share, Shannon James Samuel acquired 45,000 shares. The insider’s holdings grew to 45,000 shares worth approximately $29700.0 following the completion of this transaction.
Also, Shannon James Samuel purchased 25,000 shares, netting a total of over 17,215 in proceeds. Following the buying of shares at $0.69 each, the insider now holds 70,000 shares.
Before that, Russo Rene had added 36,289 shares to its account. In a trade valued at $24,680, the PRESIDENT AND CEO bought Xilio Therapeutics Inc shares for $0.68 each. Upon closing the transaction, the insider’s holdings increased to 36,289 shares, worth approximately $0.19 million.
As published in their initiating research note from Leerink Partners on August 06, 2025, Xilio Therapeutics Inc [XLO] has been an Outperform and the price target has been revised to $2. Analysts at Chardan Capital Markets started covering the stock with ‘”a Buy”‘ outlook in a report released in late December. As of January 10, 2022, H.C. Wainwright has initiated its “Buy” rating for XLO. Earlier on November 16, 2021, Raymond James initiated its rating. Their recommendation was “an Outperform” for XLO stock.
Analyzing XLO Stock Performance
On last trading session, Xilio Therapeutics Inc [NASDAQ: XLO] plunged -0.73% to $0.66. The stock’s lowest price that day was $0.6464, but it reached a high of $0.677 in the same session. During the last five days, there has been a surge of approximately 1.02%. Over the course of the year, Xilio Therapeutics Inc shares have dropped approximately -28.50%.
Is Xilio Therapeutics Inc subject to short interest?
Stocks of Xilio Therapeutics Inc saw a sharp rise in short interest on 2025-07-15 jumping by 0.71 million shares to 3.34 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 2.62 million shares. A jump of 21.37% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.51 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.51.
Which companies own the most shares of Xilio Therapeutics Inc (XLO)?
In terms of Xilio Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 7 in the next 12 months, up nearly 960.61% from the previous closing price of $0.66. Analysts anticipate Xilio Therapeutics Inc stock to reach 7 by 2025, with the lowest price target being 7. In spite of this, 1 analysts ranked Xilio Therapeutics Inc stock as Buy at the end of 2025. On November 16, 2021, Morgan Stanley assigned a price target of “an Overweight” to the stock and initiated coverage with a $32.
